Press release

Be The Match BioTherapies® Announces Collaboration with Poseida Therapeutics to Support Development of Life-Saving Cellular Therapies

Sponsored by Businesswire

The Match BioTherapies®
, a subsidiary of the National
Marrow Donor Program® (NMDP)/Be The Match® that
offers integrated services and software to manage the collection and
delivery of life-saving cellular therapies, today announced a
collaboration with Poseida
to provide end-to-end services to ensure timely
collection, transport and delivery of high-quality cellular starting
material to meet the specifications and needs of Poseida throughout the
development of their autologous CAR-T programs.

Poseida is preparing to begin a Phase 2 trial of P-BCMA-101 for patients
with multiple myeloma in the first half of 2019, and expects to file an
IND for P-PSMA-101 for patients with prostate cancer later in the year.
To support the advancement of both CAR-T programs, Be The Match
BioTherapies will draw on more than 30 years of experience in collection
network management and supply chain and logistics developed by the
NMDP/Be The Match. Be The Match BioTherapies plans to leverage its
established relationships and resources, including its Quality
System Audit Program (QSAP)
, to expand Poseida’s existing network of
apheresis centers and ensure the entire network is appropriately
qualified, onboarded, trained and supervised.

“Poseida’s investigational CAR-T therapies show incredible promise for
patients with high unmet medical need and further support our mission to
save lives through cellular therapy,” said Chris McClain, vice
president, New Business Development and Sales, Be The Match
BioTherapies. “We look forward to providing apheresis site qualification
through QSAP and offering end-to-end support for collection of cellular
starting material, supply chain case management and transport and
delivery, so the Poseida team can focus on advancing these programs
through the clinic and hopefully soon into the commercial arena.
Together, we hope to rapidly bring transformative cellular therapies to
people with multiple myeloma and prostate cancer.”

“We look forward to offering these therapies to the patients who need
them and may currently have limited options for effective treatment,”
said Martin Giedlin, Ph.D., vice president, Technical Operations,
Poseida Therapeutics. “The team at Be The Match BioTherapies brings deep
apheresis and logistics knowledge, as well as extensive experience, to
this collaboration and we are looking forward to working together to
more efficiently advance our lead programs.”

About Be The Match BioTherapies

The Match BioTherapies
 is the only cell and gene therapy solutions
provider with customizable services to support the end-to-end cell
therapy supply chain. Backed by the industry-leading experience of the National
Marrow Donor Program/Be The Match
, and a research partnership
with the CIBMTR® (Center
for International Blood and Marrow Transplant Research®), the
organization designs solutions that advance cell and gene therapies in
any stage of development.

Be The Match BioTherapies is dedicated to providing high-quality
cellular starting material consented for research, clinical and
commercial use, developing and managing expansive cell collection
networks, and navigating cell therapy regulatory compliance. Using
proven infrastructure to successfully manage cell therapy supply chains,
including MatchSource® Supply
Chain Software
, cell therapy supply chain case managers and
logistics experts, the organization has a history of compliance managing
the chain of identity. The collaboration with CIBMTR extends services to
include long-term follow-up tracking for the first two FDA-approved
CAR-T therapies.

For more information, follow Be The Match BioTherapies on LinkedIn or
Twitter at @BTMBioTherapies.